logo-loader
NASDAQ:KMPH

KemPharm Inc.

Receive alerts
Market:
NASDAQ
Market Cap:
-
Price
-
Change
-
52 weeks high
-
52 weeks low
-

In brief

KemPharm® believes that its LAT™ Platform technology offers potential benefits to improve drug properties by developing prodrugs that are new molecules with improved attributes over FDA-approved drugs, such as enhanced bioavailability, extended duration of action, increased safety, and reduced susceptibility to abuse.

The Iowa-based speciality pharmaceutical company discovers and develops various proprietary prodrugs in the US. The firm’s lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of ADHD.